Engineering antibodies for dual specificity and enhanced potency

Biotechnology and Bioprocess Engineering

Volumn 20, Issue 2, 2015, Pages 201-210

  Ko, Sanghwan ^a   Jung, Sang Taek ^a  

^a Kookmin University   (South Korea)

Author keywords

antibody engineering; bispecific antibody; dual specificity; therapeutic antibody

Indexed keywords

CELL ENGINEERING; MONOCLONAL ANTIBODIES;

ANTIBODY ENGINEERING; ANTIBODY FRAGMENT; ANTIBODY STRUCTURES; CHEMICAL COUPLING; DUAL SPECIFICITY; HUMAN THERAPEUTICS; IN-DEPTH UNDERSTANDING; THERAPEUTIC ANTIBODIES;

ANTIBODIES;

ANTIBODY; BISPECIFIC ANTIBODY; CATUMAXOMAB; ERTUMAXOMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; ANTIGEN RECOGNITION; CROSS LINKING; GEL FILTRATION CHROMATOGRAPHY; HUMAN; IMMUNOGENICITY; ION EXCHANGE CHROMATOGRAPHY; REVIEW;

EID: 84929454314     PISSN: 12268372     EISSN: 19763816     Source Type: Journal    
DOI: 10.1007/s12257-014-0575-6     Document Type: Review

References (54)

1. Scott, A. M., J. D. Wolchok, and L. J. Old (2012) Antibody therapy of cancer. Nat. Rev. Cancer. 12: 278–287.
2. Dimitrov, D. S. (2012) Therapeutic proteins: Methods in Molecular Biology. 2nd ed., pp. 1–26. Humana Press, NY, USA.
3. Weis, S. M. and D. A. Cheresh (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17: 1359–1370.
4. May, C., P. Sapra, and H.-P. Gerber (2012) Advances in bispecific biotherapeutics for the treatment of cancer. Biochem. Pharmacol. 84: 1105–1112.
5. Scheuer, W., T. Friess, H. Burtscher, B. Bossenmaier, J. Endl, and M. Hasmann (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 69: 9330–9336.
6. Li, B., Y. Meng, L. Zheng, X. Zhang, Q. Tong, W. Tan, S. Hu, H. Li, Y. Chen, J. Song, G. Zhang, L. Zhao, D. Zhang, S. Hou, W. Qian, and Y. Guo (2013) Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res. 73: 6471–6483.
7. Sebastian, M. (2010) Review of catumaxomab in the treatment of malignant ascites. Cancer Manag. Res. 2: 283–286.
8. Seimetz, D., H. Lindhofer, and C. Bokemeyer (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. 36: 458–467.
9. Milstein, C. and A. C. Cuello (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305: 537–540.
10. Tarditi, L., M. Camagna, A. Parisi, C. Vassarotto, L. B. DeMonte, M. Letarte, F. Malavasi, and M. Mariani (1992) Selective highperformance liquid chromatographic purification of bispecific monoclonal antibodies. J. Chromatogr. A. 599: 13–20.
11. Lindhofer, H., R. Mocikat, B. Steipe, and S. Thierfelder (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155: 219–225.
12. Zeidler, R., J. Mysliwietz, M. Csanady, A. Walz, I. Ziegler, B. Schmitt, B. Wollenberg, and H. Lindhofer (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer. 83: 261–266.
13. Jäger, M., A. Schoberth, P. Ruf, J. Hess, and H. Lindhofer (2009) The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 69: 4270–4276.
14. Nisonoff, A. and M. M. Rivers (1961) Recombination of a mixture of univalent antibody fragments of different specificity. Arch. Biochem. Biophys. 93: 460–462.
15. Pullarkat, V., Y. Deo, J. Link, L. Spears, V. Marty, R. Curnow, S. Groshen, C. Gee, and J. S. Weber (1999) A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol. Immun. 48: 9–21.
16. Fury, M., A. Lipton, K. Smith, C. Winston, and D. Pfister (2008) A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol. Immun. 57: 155–163.
17. Hartmann, F., C. Renner, W. Jung, C. Deisting, M. Juwana, B. Eichentopf, M. Kloft, and M. Pfreundschuh (1997) Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood. 89: 2042–2047.
18. Doppalapudi, V. R., J. Huang, D. Liu, P. Jin, B. Liu, L. Li, J. Desharnais, C. Hagen, N. J. Levin, M. J. Shields, M. Parish, R. E. Murphy, J. DelRosario, B. D. Oates, J. Y. Lai, M. J. Matin, Z. Ainekulu, A. Bhat, C. W. Bradshaw, G. Woodnutt, R. A. Lerner, and R. W. Lappe (2010) Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. U S A. 107: 22611–22616.
19. Kim, C. H., J. Y. Axup, A. Dubrovska, S. A. Kazane, B. A. Hutchins, E. D. Wold, V.V. Smider, and P.G. Schultz (2012) Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. J. Am. Chem. Soc. 134: 9918–9921.
20. Kolb, H. C., M. G. Finn, and K. B. Sharpless (2001) Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40: 2004–2021.
21. Segal, D. M., G. J. Weiner, and L. M. Weiner (1999) Bispecific antibodies in cancer therapy. Curr. Opin. Immunol. 11: 558–562.
22. Arndt, K. M., K. M. Müller, and A. Plückthun (1998) Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochem. 37: 12918–12926.
23. Holliger, P., T. Prospero, and G. Winter (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA. 90: 6444–6448.
24. Arndt, M. A., J. Krauss, S. M. Kipriyanov, M. Pfreundschuh, and M. Little (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood. 94: 2562–2568.
25. Unverdorben, F., A. Färber-Schwarz, F. Richter, M. Hutt, and R. E. Kontermann (2012) Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A. Protein Eng. Des. Sel. 25: 81–88.
26. Zhu, Z., L. G. Presta, G. Zapata, and P. Carter (1997) Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 6: 781–788.
27. Johnson, S., S. Burke, L. Huang, S. Gorlatov, H. Li, W. Wang, W. Zhang, N. Tuaillon, J. Rainey, B. Barat, Y. Yang, L. Jin, V. Ciccarone, P. A. Moore, S. Koenig, and E. Bonvini (2010) Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 399: 436–449.
28. Baeuerle, P. A., P. Kufer, and R. Bargou (2009) BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Mol. Ther. 11: 22–30.
29. Nagorsen, D., P. Kufer, P. A. Baeuerle, and R. Bargou (2012) Blinatumomab: A historical perspective. Pharmacol. Therapeut. 136: 334–342.
30. Mack, M., G. Riethmüller, and P. Kufer (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. USA. 92: 7021–7025.
31. Bargou, R., E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler, H. Einsele, C. Brandl, A. Wolf, P. Kirchinger, P. Klappers, M. Schmidt, G. Riethmüller, C. Reinhardt, P. A. Baeuerle, and P. Kufer (2008) Tumor regression in cancer patients by very low doses of a T cell–engaging antibody. Sci. 321: 974–977.
32. Roopenian, D. C. and S. Akilesh (2007) FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7: 715–725.
33. Jung, S. (2013) Tailoring immunoglobulin Fc for highly potent and serum-stable therapeutic antibodies. Biotechnol. Bioproc. Eng. 18: 625–636.
34. Wu, C., H. Ying, S. Bose, R. Miller, L. Medina, L. Santora, and T. Ghayur (2009) Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules. MAbs. 1: 339–347.
35. Wu, C., H. Ying, C. Grinnell, S. Bryant, R. Miller, A. Clabbers, S. Bose, D. McCarthy, R.-R. Zhu, L. Santora, R. Davis-Taber, Y. Kunes, E. Fung, A. Schwartz, P. Sakorafas, J. Gu, E. Tarcsa, A. Murtaza, and T. Ghayur (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25: 1290–1297.
36. Correia, I., J. Sung, R. Burton, C. G. Jakob, B. Carragher, T. Ghayur, and C. Radziejewski (2013) The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. MAbs. 5: 364–372.
37. Chames, P. and D. Baty (2009) Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 1: 539–547.
38. Ridgway, J. B. B., L. G. Presta, and P. Carter (1996) ‘Knobs-intoholes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9: 617–621.
39. Atwell, S., J. B. B. Ridgway, J. A. Wells, and P. Carter (1997) Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 270: 26–35.
40. Merchant, A. M., Z. Zhu, J. Q. Yuan, A. Goddard, C. W. Adams, L. G. Presta, and P. Carter (1998) An efficient route to human bispecific IgG. Nat. Biotechnol. 16: 677–681.
41. Schiffer, M., C. H. Chang, V. M. Naik, and F. J. Stevens (1988) Analysis of immunoglobulin domain interactions: Evidence for a dominant role of salt bridges. J. Mol. Biol. 203: 799–802.
42. Gunasekaran, K., M. Pentony, M. Shen, L. Garrett, C. Forte, A. Woodward, S. B. Ng, T. Born, M. Retter, K. Manchulenko, H. Sweet, I. N. Foltz, M. Wittekind, and W. Yan (2010) Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Application to bispecific molecules and monovalent IgG. J. Biol. Chem. 285: 19637–19646.
43. Suresh, M. R., A. C. Cuello, and C. Milstein (1986) Bispecific monoclonal antibodies from hybrid hybridomas. pp. 210–228. In: H. V. V. John and J. Langone (ed.). Methods in Enzymology. Academic Press, USA.
44. Wranik, B. J., E. L. Christensen, G. Schaefer, J. K. Jackman, A. C. Vendel, and D. Eaton (2012) LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J. Biol. Chem. 287: 43331–43339.
45. Schaefer, W., J. T. Regula, M. Bähner, J. Schanzer, R. Croasdale, H. Dürr, C. Gassner, G. Georges, H. Kettenberger, S. Imhof-Jung, M. Schwaiger, K. G. Stubenrauch, C. Sustmann, M. Thomas, W. Scheuer, and C. Klein (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. USA. 108: 11187–11192.
46. Spiess, C., M. Merchant, A. Huang, Z. Zheng, N.-Y. Yang, J. Peng, D. Ellerman, W. Shatz, D. Reilly, D. G. Yansura, and J. M. Scheer (2013) Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat. Biotechnol. 31: 753–758.
47. Spiess, C., J. Bevers, J. Jackman, N. Chiang, G. Nakamura, M. Dillon, H. Liu, P. Molina, J. M. Elliott, W. Shatz, J. M. Scheer, G. Giese, J. Persson, Y. Zhang, M. S. Dennis, J. Giulianotti, P. Gupta, D. Reilly, E. Palma, J. Wang, E. Stefanich, H. Scheerens, G. Fuh, and L. C. Wu (2013) Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J. Biol. Chem. 288: 26583–26593.
48. Jung, S. T., S. T. Reddy, T. H. Kang, M. J. Borrok, I. Sandlie, P. W. Tucker, and G. Georgiou (2010) Aglycosylated IgG variants expressed in bacteria that selectively bind FcãRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. USA. 107: 604–609.
49. Jung, S. T., W. Kelton, T. H. Kang, S. T. W. Ng, J. T. Andersen, I. Sandlie, C. A. Sarkar, and G. Georgiou (2013) Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcãRIIa affinity and selectivity. ACS Chem. Biol. 8: 368–375.
50. Jung, S. T., T. H. Kang, W. Kelton, and G. Georgiou (2011) Bypassing glycosylation: engineering aglycosylated full length IgG antibodies for human therapy. Curr. Opin. Biotechnol. 22: 858–867.
51. Ju, M. S. and S. T. Jung (2014) Aglycosylated full-length IgG antibodies: Steps toward next-generation immunotherapeutics. Curr. Opin. Biotechnol. 30: 128–139.
52. Sazinsky, S. L., R. G. Ott, N. W Silver, S. Tidor, J. V. Ravetch, and K. D. Wittrup (2008) Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. USA. 105: 20167–20172.
53. Jung, S. T., T. H. Kang, and D. I. Kim (2014) Engineering an aglycosylated Fc variant for enhanced FcãI engagement and pHdependent human FcRn binding. Biotechnol. Bioproc. Eng. in press
54. Bostrom, J., S.-F. Yu, D. Kan, B. A. Appleton, C. V. Lee, K. Billeci, W. Man, F. Peale, S. Ross, C. Wiesmann, and G. Fuh (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Sci. 323: 1610–1614.